Table 2.
Follow up time and vaccines received in included patients.
| N = 576 | |
|---|---|
| Median follow up time after second dose, days (SD) | 94 ± 21 |
| Mean follow up time after second dose, days | 91 ± 17 |
| Previous covid infection, n (%) | 55 (9.54%) |
| First dose vaccine received | |
| Sputnik V, n (%) | 172 (29.86%) |
| Astra Zeneca, n (%) | 283(49.3%) |
| Sinopharm | 106 (18.40%) |
| Jansens | 15(2.6%) |
| Second dose vaccine received | |
| Sputnik V, n (%) | 123(21.35%) |
| Astra Zeneca, n (%) | 312(54.16%) |
| Sinopharm | 94 (16.3%) |
| Moderna | 26 (4.51) |
| Pfizer | 21(3.64) |
| Median time between first and second vaccine dose, (SD) | 55±18 |
| Homologous vaccine scheme, n (%) | 475 (82.5) |
| Heterologous vaccine scheme, n (%) | 101 (17.5) |
SD= standard deviation.